单克隆抗体应对最终药物的生产,配制,递送和稳定性方面的挑战 407条(本栏目收费,不能显示细节,电话15274084725)
silicone oil interactions with proteins and mAbs,155,156 156
viscous solutions delivery using,153,154 154
primary container/closure systems,154,155 155
silicone oil interactions with proteins and mAbs,155,156 156
technical challenges for device and formulation development,154 154
Di-2-ethylhexyl-phthalate (DEHP),121,122 122
Diafiltration unit operations,78,79 79
Differential scanning calorimetry (DSC),32,33,70,136 136
Diffusion coefficient,169 169
3;4-dihydroxyphenylalanine (DOPA),56,58 58
Dosage form assessment—solid vs. liquid dosage forms,93,103 103
Drug product (DP),2,139,140 140
large-scale pumps in,78 78
Drug antibody ratio (DAR),193,194 194
Dynamic light scattering (DLS),32,168 168
DLS interaction parameter,172,174 174
Einstein’s equation,143,145 145
Electrophoretic methods CE,23,24 24
isoelectric focusing,22,23 23
reduced and nonreduced sodium dodecyl sulfate electrophoresis,21,22 22
Enzyme-linked immunosorbent assay(ELISA),36 36
Erythropoietin (EPO),157 157